Our findings reveal that scAAV6-NeuroD1 preferentially infects glioma cells and induces dual therapeutic effects by simultaneously inhibiting glioma cell proliferation and inducing neuronal reprogramming. The gene discussed is NEUROD1; the disease is central nervous system cancer.